Comparison of the discriminative stimulus effects of salvinorin A and its derivatives to U69,593 and U50,488 in rats.
Lisa E Baker, John J Panos, Bryan A Killinger, Mary M Peet, Lisa M Bell, Larissa A Haliw, Sheryl L Walker
Psychopharmacology April 1, 2009 DOI: 10.1007/s00213-008-1458-3 via PubMed
Summary
AI-generated from the abstractSalvinorin A, the active compound in the hallucinogenic plant Salvia divinorum, produces its effects through kappa opioid receptors. In experiments with male Sprague-Dawley rats trained to discriminate between two different kappa opioid agonists (U69,593 or U50,488), salvinorin A and two synthetic derivatives of salvinorin B fully substituted for the training drugs, indicating they produce similar internal sensations. Additional rats trained to discriminate salvinorin A also recognized the other kappa agonists. These results confirm that salvinorin A's discriminative stimulus effects are mediated by kappa receptors, supporting the potential use of salvinorin A analogs as therapeutic agents for conditions like drug dependence and mood disorders.
Study at a glance
| Characteristics | Animal experiment with drug discrimination training Peer reviewed |
|---|---|
| Sample size | 24 |
| Population | Male Sprague-Dawley rats |
| Interventions | Salvinorin A U69 593 U50 488 salvinorin B ethoxymethyl ether salvinorin B methoxymethyl ether |
| Dose | 0.125-3.0 mg/kg (salvinorin A), 0.13 mg/kg (U69,593), 3.0 mg/kg (U50,488), 0.005-0.10 mg/kg (salvinorin B ethoxymethyl ether), 0.03-0.10 mg/kg (salvinorin B methoxymethyl ether) |
| Topics | Addiction Salvia divinorum |
| Keywords | Plant compound Synthetic cousins Derivatives Therapeutic potential |
| Citations | 57 |
| Key finding | Salvinorin A and two synthetic derivatives of salvinorin B fully substituted for kappa opioid agonists U69,593 and U50,488 in drug discrimination tests, confirming that salvinorin A's discriminative stimulus effects are mediated by kappa receptors. |
Abstract
Research interests regarding the psychopharmacology of salvinorin A have been motivated by the recreational use and widespread media focus on the hallucinogenic plant, Salvia divinorum. Additionally, kappa opioid (KOP) receptor ligands may have therapeutic potential in the treatment of some neuropsychiatric conditions, including drug dependence and mood disorders. Salvinorin A is a selective KOP agonist, but only a few studies have explored the discriminative stimulus effects of this compound. This study compared the discriminative stimulus effects of salvinorin A and two synthetic derivatives of salvinorin B to the KOP agonists, U69,593 and U50,488. Sixteen male Sprague-Dawley rats trained to discriminate U69,593 (0.13 mg/kg, s.c., N = 8) or U50,488 (3.0 mg/kg, i.p., N = 8) under a fixed-ratio 20 schedule of food reinforcement were administered substitution tests with salvinorin A (0.125-3.0 mg/kg, i.p.). The animals trained to discriminate U69,593 were also administered substitution tests with salvinorin B ethoxymethyl ether (0.005-0.10 mg/kg, i.p.) and salvinorin B methoxymethyl ether (0.03-0.10 mg/kg, i.p.). Another eight rats were trained to discriminate 2.0 mg/kg salvinorin A and tested with U69,593 (0.04-0.32 mg/kg) and U50,488 (0.4-3.2 mg/kg). Salvinorin A and both synthetic derivatives of salvinorin B substituted completely for U69,593. Additionally, cross-generalization was observed between salvinorin A and both KOP agonists. These findings support previous reports indicating that the discriminative stimulus effects of salvinorin A are mediated by kappa receptors. Future studies may assist in the development and screening of salvinorin A analogs for potential pharmacotherapy.